Retrospective, Multicenter Observational Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma After at Least Two Lines of Therapy Within the Compassionate Use Program

What this Trial Is About

This research aims to evaluate the response to treatment with Mosunetuzumab in adults with relapsed or refractory Follicular Lymphoma who have already received at least two lines of therapy. The study is retrospective and observational, collecting data from multiple centers to understand how Mosunetuzumab performs within a Compassionate Use Program. It focuses on patients with Follicular Non-Hodgkin Lymphoma treated under this program and overseen by lead sponsor Andrés José Maria Ferreri. Participants in this study have been treated with Mosunetuzumab, a drug administered as part of the Compassionate Use Program for those with relapsed or refractory Follicular Lymphoma after two or more prior therapies. The study collects information retrospectively and does not involve assigning treatments or interventions directly. The observation period includes up to one year from the start of treatment. During participation, researchers will evaluate treatment response using the Lugano criteria and measure disease-free survival over one year. They will also review overall survival and toxicity rates at 12 months. The study relies on patient records and treatment data without requiring additional procedures. Participants’ usual care continues as normal, and the total observation period lasts up to one year after treatment initiation.

Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).